LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Strona główna・Stock List・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Closed

SectorHealthcare

31.17 0.06

Buy Sell

Overview

Share price change

24h

Current

Min

31.16

Max

31.17

Key metrics
By Trading Economics
Income	11M 64M
Sales	-3.2M 149M
P/E Sector Avg	18.542 51.415
EPS	0.68
Profit margin	42.663
Employees	182
EBITDA	-7.8M 73M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+6.16% upside

Dividends
By Dow Jones
Next Earnings	5 sie 2026

Market Stats
By TradingEconomics
Market Cap	271M 3.8B
Previous open	31.11
Previous close	31.17

News Sentiment

By Acuity

50%

137 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

N/A / 24.28 Support & Resistance

Catalyst Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 maj 2026, 22:47 UTC

Hot Stocks

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 maj 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 maj 2026, 22:00 UTC

Major Market Movers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 maj 2026, 18:09 UTC

Major Market Movers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 maj 2026, 16:02 UTC

Earnings

Major Market Movers

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 maj 2026, 14:55 UTC

Major Market Movers

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

16 maj 2026, 16:27 UTC

Acquisitions, Mergers, Takeovers

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 maj 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 maj 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 maj 2026, 21:59 UTC

Acquisitions, Mergers, Takeovers

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 maj 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 maj 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 maj 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 maj 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 maj 2026, 20:19 UTC

Hot Stocks

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 maj 2026, 19:41 UTC

Acquisitions, Mergers, Takeovers

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 maj 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 maj 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 maj 2026, 18:35 UTC

Earnings

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 maj 2026, 17:28 UTC

Market Talk

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 maj 2026, 16:50 UTC

Acquisitions, Mergers, Takeovers

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 maj 2026, 16:24 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 maj 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15 maj 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 maj 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 maj 2026, 15:55 UTC

Market Talk

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 maj 2026, 15:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 maj 2026, 15:20 UTC

Market Talk

Silver Plunges on Inflation Worries -- Market Talk

15 maj 2026, 15:20 UTC

Earnings

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

Peer Comparison

Price change

Catalyst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

6.16% upside

12 Months Forecast

Average 33.1 USD 6.16%

High 35 USD

Low 31.5 USD

Based on 7 Wall Street analysts offering 12 month price targets forCatalyst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Catalyst Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 24.28Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

137 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.